Slide 1: IBA Third-quarter 2025 update
IBA Third-quarter 2025 update November 20th, 2025 PUBLIC
Slide 2: Disclaimer
Disclaimer • This presentation may contain forward-looking statements. • All statements other than statements of historical facts, including statements regarding IBA’s objectives, plans, goals, strategies, future growth and growth drivers, industry outlook, future orders, revenue, backlog, earnings
Slide 3: Today's speakers and agenda
Today’s speakers and agenda Highlights Catherine Vandenborre Summary of key achievements for the period Chief Financial Officer Corporate refinancing Overview of rationale & key terms Thomas Pevenage Head of Investor Relations 3 PUBLIC
Slide 4: Highlights: confident to meet FY2025 guidance
Highly confident to meet FY2025 guidance supported by well under control OpEx and already positive PT REBIT HIGHLIGHTS vs. Q3 2024 comparable figures 2025 OpEx PT REBIT Guidance REBIT < 30% > €25M total sales > €0M reaffirmed Under control Positive contribution Order intake Backlog Net debt position
Slide 5: Strategic progress across business segments in Q3 2025
Strategic progress across business segments in Q3 2025 HIGHLIGHTS IBA Clinical IBA Technologies Proton Therapy Dosimetry Industrial RadioPharma • Signature of Memorandum • High volume product my • Ongoing regulatory • Strong commercial traction of Understanding with QA Blue Phantom for pressure on E
Slide 6: Financing package - rationale
Financing package - rationale CORPORATE REFINANCING Half Year 2025 Results press release: “IBA’s Management is reviewing the Group’s financial structure to ensure it remains aligned with the evolving working capital cycle and planned strategic investments.” Closing of a €135 million refinancing pa
Slide 7: Outcome: A EUR million debt refinancing package
Outcome: A EUR 135 million debt refinancing package addressing IBA’s current and future needs CORPORATE REFINANCING Up to 135 M€ used 135 M€ available Subordinated Loan from Wallonie 10 Entreprendre Optimization of balance sheet • 6-year, balloon profile • Long-term liabilities vs. long- term assets
Slide 8: Currently, M€ drawn and M€ available, providing flexibility
Currently, 61 M€ drawn and 74 M€ available, providing flexibility CORPORATE REFINANCING Amounts in M€ Available 60 50 20 39 15 30 10 21 15 10 Subordinated 5-year Term Loan M&A Term Loan Revolving 8 PUBLIC
Slide 9: Conclusion: A financing structure that is…
Conclusion: A financing structure that is… CORPORATE REFINANCING Secured Committed over 5 years Coordinator & agent Optimized Long-term vs. short-term Flexible Volatility of working cap, investment opportunities Robust Strong financing partners 9 PUBLIC
Slide 10: Any question?
Any question? PUBLIC